Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and ...
With the possibility of Robert F. Kennedy, Jr. being involved in health policy in the next administration, vaccination – ...
They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...
Like humans and other complex multicellular organisms, single-celled bacteria can fall ill and fight off viral infections. A ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...
Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...
SINGAPORE: In a bid to bolster Singapore’s healthcare resilience, the country has launched Asia’s first fully automated mRNA ...